Figure 2.

Future challenges of metabolomic studies. Translational research could accelerate the development of cardioprotective agents to be introduced rapidly in clinical practice. On the other hand, the identification of metabolite clusters associated with the risk of developing cardiotoxicity (CTX) could allow an early therapeutic intervention, before the occurrence of clinical events. Abbreviations: RCT: randomised clinical trials; ACEi: ACE-inhibitors; ARBs: angiotensin receptor blockers; BBs: beta-blockers; HF: heart failure.